Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $168.2 million.

  • Avidity Biosciences' Non-Current Assets rose 78966.94% to $168.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $332.3 million, marking a year-over-year increase of 36291.01%. This contributed to the annual value of $21.6 million for FY2024, which is 2526.09% up from last year.
  • Latest data reveals that Avidity Biosciences reported Non-Current Assets of $168.2 million as of Q3 2025, which was up 78966.94% from $118.4 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Non-Current Assets peaked at $168.2 million during Q3 2025, and registered a low of $2.8 million during Q1 2021.
  • Its 5-year average for Non-Current Assets is $28.7 million, with a median of $16.8 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 353.43% in 2022, then skyrocketed by 78966.94% in 2025.
  • Over the past 5 years, Avidity Biosciences' Non-Current Assets (Quarter) stood at $16.4 million in 2021, then fell by 3.53% to $15.9 million in 2022, then grew by 8.77% to $17.2 million in 2023, then rose by 25.26% to $21.6 million in 2024, then surged by 678.49% to $168.2 million in 2025.
  • Its last three reported values are $168.2 million in Q3 2025, $118.4 million for Q2 2025, and $24.1 million during Q1 2025.